| P50 | author | Peter H. Cashin | Q50945433 |
| P2093 | author name string | Helgi Birgisson | |
| | Johan Botling | |
| | Alexei Terman | |
| | Wilhelm Graf | |
| | Lana Ghanipour | |
| | Malin Enblad | |
| P2860 | cites work | Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? | Q87140434 |
| | Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer | Q24556616 |
| | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy | Q26769870 |
| | KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. | Q27824867 |
| | KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice | Q33759960 |
| | Peritonectomy procedures | Q34316366 |
| | Immunohistochemistry - microarray analysis of patients with peritoneal metastases of appendiceal or colorectal origin | Q34867868 |
| | Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer | Q35191237 |
| | Clinicopathological Parameters in Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Metastases: A Meta-analysis | Q35891567 |
| | KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases | Q36071767 |
| | Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. | Q36416491 |
| | BRAF-Directed Therapy in Metastatic Colorectal Cancer | Q37041765 |
| | Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication | Q37075412 |
| | The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis | Q38214032 |
| | Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. | Q38699358 |
| | Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. | Q38847613 |
| | Cytoreduction and hyperthermic intraperitoneal chemotherapy (CS/HIPEC) in colorectal cancer: Evidence-based review of patient selection and treatment algorithms | Q39060897 |
| | Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes | Q39212979 |
| | Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. | Q40209192 |
| | Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. | Q41146040 |
| | A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction | Q41159551 |
| | Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. | Q41666883 |
| | Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study | Q47582754 |
| | External Validation of the Prognostic Nomogram (COMPASS) for Patients with Peritoneal Carcinomatosis of Colorectal Cancer | Q47998828 |
| | Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: an observational cohort study. | Q50945368 |
| | High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. | Q51245526 |
| | Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. | Q54290348 |
| | Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin | Q57108862 |
| | Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin | Q57279830 |
| | Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis | Q79662626 |
| | HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples | Q86101287 |
| P433 | issue | 1 | |
| P921 | main subject | peritoneal carcinomatosis | Q2071182 |
| P304 | page(s) | 293-300 | |
| P577 | publication date | 2019-09-30 | |
| P1433 | published in | Annals of Surgical Oncology | Q2853069 |
| P1476 | title | Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC | |
| P478 | volume | 27 | |